Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests Illustration of a semaglutide peptide (blue) bound to its target glucagon-like peptide-1 (GLP-1, light pink).